@article {Olbei2020.11.14.20231878, author = {Marton Olbei and Isabelle Hautefort and Dezso Modos and Agatha Treveil and Martina Poletti and Lejla Gul and Claire D Shannon-Lowe and Tamas Korcsmaros}, title = {SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients}, elocation-id = {2020.11.14.20231878}, year = {2020}, doi = {10.1101/2020.11.14.20231878}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Hyper-induction of pro-inflammatory cytokines, also known as a cytokine storm or cytokine release syndrome (CRS) is one of the key aspects of the currently ongoing SARS-CoV-2 pandemic. This process occurs when a large number of innate and adaptive immune cells are activated, and start producing pro-inflammatory cytokines, establishing an exacerbated feedback loop of inflammation. It is one of the factors contributing to the mortality observed with COVID-19 for a subgroup of patients. CRS is not unique to SARS-CoV-2 infection; it was prevalent in most of the major human coronavirus and influenza A subtype outbreaks of the past two decades (H5N1, SARS-CoV, MERS-CoV, H7N9). Here, we collected changing cytokine levels upon infection with the aforementioned viral pathogens through a comprehensive literature search. We analysed published patient data to highlight the conserved and unique cytokine responses caused by these viruses. A map of such responses could help specialists identify interventions that successfully alleviated CRS in different diseases and evaluate whether they could be used in COVID-19 cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.O., A.T., L.G., and M.P. are supported by the UKRI Biotechnological and Biosciences Research Council (BBSRC) funded Norwich Research Park Biosciences Doctoral Training Partnership (grant numbers BB/M011216/1 and BB/S50743X/1). The work of T.K., D.M., and I.H. was supported by the Earlham Institute (Norwich, UK) in partnership with the Quadram Institute (Norwich, UK) and strategically supported by the UKRI BBSRC UK grants (BB/J004529/1, BB/P016774/1, and BB/CSP17270/1). C.D.S. was supported by MRC MR/N023781/1 and the Histiocytosis Society, USA. T.K. and D.M. were also funded by a BBSRC ISP grant for Gut Microbes and Health BB/R012490/1 and its constituent projects, BBS/E/F/000PR10353 and BBS/E/F/000PR10355. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study only contains literature based meta analyses for which no ethical approval or oversight were needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll associated data can be found in the supplementary tables, and on the github page linked in the manuscript, in the methods section.}, URL = {https://www.medrxiv.org/content/early/2020/11/16/2020.11.14.20231878}, eprint = {https://www.medrxiv.org/content/early/2020/11/16/2020.11.14.20231878.full.pdf}, journal = {medRxiv} }